Introduction
Oral phosphodiesterase type 5 (PDE5) inhibitors are the recommended first-line option for the treatment of erectile dysfunction. Currently, three PDE5 inhibitors are approved for use in the United States: sildenafil citrate (sildenafil), vardenafil HCl (vardenafil) and tadalafil. All three drugs have similar efficacy and toxicity profiles. 1 Minor differences exist between the three PDE5 inhibitors. Tadalafil has a longer duration of action and its pharmacokinetic profile is not affected by food, as compared to sildenafil and vardenafil. Vardenafil does not alter color perception through inhibition of phosphodiesterase type 6, a rare side effect of sildenafil. 2 However, all three drugs are well tolerated with few reported serious adverse events.
Several studies have been conducted to evaluate patient preference for a particular PDE5 inhibitor. The majority of these studies seem to indicate a preference for tadalafil, the longer acting agent, as opposed to sildenafil and vardenafil, the two shorter acting agents. These preference studies have been criticized for their design flaws, which hinder interpretation of the data. 3 The National Veterans Administration (VA) recently switched its preferred formulary agent for the treatment of erectile dysfunction from sildenafil to vardenafil for financial reasons. 4 This change provided a unique opportunity to evaluate the interchangeability of two of the PDE5 inhibitors in the clinical setting. In contrast to the background of other studies, the impetus for the formulary change in this case was an economic one. The cost related to therapy for erectile dysfunction has greatly increased in recent years. 5 As more men seek treatment, this cost will continue to rise and the economics of pharmacological therapies will become increasingly important. As part of the Urologic Diseases in America project, Wessells et al. 5 estimated that the cost of treatment for erectile dysfunction could reach $15 billion if all men sought treatment. In the face of such substantial expenditures, price is a principal factor in the choice between phosphodiesterase inhibitors. According to data published by the VA Pharmacy Benefits Management Strategic Healthcare Group, the cost to the VA for a 30-day supply of vardenafil at a 20 mg dose is $173.83, while the same quantity of a 50 or 100 mg dose of sildenafil cost the VA $228.32, resulting in a savings of $44.49 for every 30-day prescription filled. 6 The objective of this study was to assess the impact of the formulary change from sildenafil to vardenafil at a local VA hospital. Given the limited data comparing these medications, patient response was difficult to predict. Under VA regulations, sildenafil remains available, but only after approval of a non-formulary request initiated by the health care practitioner prescribing the medication. This availability provided the basis for carrying out the study design. To gain approval for sildenafil, the patient must be classified as a vardenafil nonresponder, be intolerant of vardenafil, or have a contraindication to vardenafil use. Criteria for vardenafil non-responders have been established by VA guidelines. 7 
Materials and methods
Approval for the study was obtained from the local VA institutional review board. The VA made the formulary change from sildenafil to vardenafil in January 2006. From pharmacy records at a local VA hospital, a list of those patients was obtained for whom sildenafil was requested after the formulary replaced sildenafil with vardenafil as the preferred agent for the indication of erectile dysfunction. All non-formulary requests were made consecutively between January 2006 and September 2006.
For all patients with non-formulary requests on file, retrospective chart review of their records was conducted. The information from the non-formulary requests was analyzed to assess the basis for prescribing sildenafil.
All patient information collected was de-identified and kept confidential according to VA Research Data Security and Privacy policies. 8 Patients for whom sildenafil was requested for an indication other than erectile dysfunction (for example pulmonary hypertension, post-prostatectomy daily therapy) were excluded from the review.
Results
A total of 169 non-formulary requests were made and accepted for sildenafil between January 2006 and September 2006 for the indication of erectile dysfunction at the study location. Eighty-nine (53%) requests were made for therapeutic failure of vardenafil in patients who were previously satisfied with sildenafil. Seven (4%) requests were made for therapeutic failure of vardenafil in patients who had never tried sildenafil. Thirty-five (21%) requests were made for adverse reactions to vardenafil in patients who were previously satisfied with sildenafil. Six of these 35 patients also complained of therapeutic failure of vardenafil. Three (2%) requests were made for adverse reactions to vardenafil in patients who had never tried sildenafil. One of these three patients also complained of therapeutic failure of vardenafil. The most common adverse reactions reported by patients included headache, dizziness, nausea, stomach upset, flushing and visual changes.
Finally, 35 (21%) requests were made for drugdrug interactions with antiarrhythmic medications due to concerns over possible QT prolongation with vardenafil. These patients did not try vardenafil. There were no serious adverse events reported by any patients or providers.
During the same time period, the pharmacy at this local VA hospital filled vardenafil prescriptions for 7657 patients.
Discussion
Limited trials comparing the three PDE5 inhibitors have been conducted. Moore et al. 9 published an indirect comparison of PDE5 inhibitors for erectile dysfunction using published randomized trials for each drug. Although analysis was severely limited by differential reporting of outcomes, the three agents were found to be similar for consistently reported efficacy numbers. Berner et al. 10 performed a comparative meta-analysis of PDE5 inhibitors looking at fixed-dose regimen randomized-controlled trials using a common outcomes measurement, the International Index of Erectile Function. Interestingly, sildenafil was found to be significantly more effective than vardenafil although all three agents were highly efficacious. However, in a randomized, double-blind crossover study in men with cardiovascular risk factors, Rubio-Aurioles et al. 11 concluded non-inferiority of vardenafil for overall preference and nominal statistical superiority of vardenafil over sildenafil for several frequently used efficacy measures.
Several studies have also been designed to evaluate patient preference between the available PDE5 inhibitors. The trend in these studies has been to conclude that patients prefer tadalafil over sildenafil and vardenafil. In an open-label study, most patients currently taking sildenafil who were given tadalafil preferred to continue on tadalafil after 9 weeks of treatment. 12 Similarly, 71% of men naive to PDE5 inhibitor therapy chose to continue on tadalafil versus 29% on sildenafil after 12 weeks of treatment with each agent in another open label study. 13 Two randomized trials found tadalafil to be preferred over sildenafil by patients with erectile dysfunction but these trials did not compare equivalent dosages of the medications.
14,15 Tolra et al. 16 conducted a prospective, randomized, openlabel, crossover study to assess patient preference and found patients preferred tadalafil over sildenafil as well as over vardenafil. Finally, in a recent prospective observational study of 2425 men, a higher percentage of patients preferred tadalafil after switching from sildenafil to tadalafil or vice versa. 17 The impact of formulary replacement of sildenafil M Singh and AD Seftel
The methodology and design of these preference studies has been criticized making interpretation of the results difficult. 3 Moreover, there have been data published that conflict with the conclusion that tadalafil is preferred by most men with erectile dysfunction. Two separate studies, one in the United States 18 and one in the United Kingdom, 19 showed that patients who were prescribed sildenafil were significantly less likely to switch to another PDE5 inhibitor compared with those who were initially prescribed vardenafil or tadalafil.
With such limited and conflicting data, the impact of switching patients from one PDE5 inhibitor to another was difficult to predict. The decision by the VA to change its formulary agent for erectile dysfunction treatment from sildenafil to vardenafil provided the opportunity to assess such a move in the clinical setting. Overall, the formulary change from sildenafil to vardenafil appeared to be well tolerated without complaints or serious side effects by the vast majority of patients at this local VA hospital. Therefore, the substantial cost savings to the VA seemed to be justified by the minimal adverse effects on patients treated for erectile dysfunction.
When others have analyzed the economic impact of PDE5 inhibitor switching, changing medications have resulted in an increase in overall expenditures. In a Pfizer study, costs attributable to erectile dysfunction and overall costs were 41 and 43% higher, respectively, for patients who switched from sildenafil to another PDE5 inhibitor compared with those who refilled sildenafil. 20 These data were based on an aggregated health care claims database. Consequently, the differential costs between sildenafil and the other PDE inhibitors were not directly reflected. The VA was able to save money with its formulary change by choosing the least expensive medication and directly achieving an economic advantage for each prescription filled.
Several interesting questions highlighted the limitations of this retrospective study and could provide the framework for further research on PDE5 inhibitor comparison. For example, an extremely small proportion of patients made a non-formulary request for sildenafil after receiving vardenafil. However, the majority of these non-formulary requests were made by patients who were previously satisfied with sildenafil and complained of therapeutic failure of vardenafil. This observation raised the issue of whether patients who were switched to vardenafil were aware of the formulary change and if they had knowledge of the ability to switch back to sildenafil if they were not satisfied. This question of access may have biased the results of the study.
Another limitation of the study was in its ability to evaluate the response of vardenafil in patients who were sildenafil-naive versus those who were previously taking sildenafil. As noted earlier, the majority of non-formulary requests were made for patients who were previously satisfied with sildenafil. It was unclear how many of the 7657 patients with active vardenafil prescriptions had previously tried sildenafil. It was also unclear what proportion of those patients who had not tried another PDE5 inhibitor were offered sildenafil or other treatments for erectile dysfunction after vardenafil failure.
Finally, there were unanswered questions on the status of those patients who had previously failed or were intolerant to sildenafil. It was unknown whether these patients were offered a trial of vardenafil or alternative treatments and the outcomes of these interventions.
The biases and limitations mentioned above stemmed from the design of the study and set the stage for prospective randomized-controlled studies which could truly answer some of the questions regarding the differential efficacy and interchangeability of the various PDE5 inhibitors in the clinical setting. In this retrospective review, it appeared that sildenafil and vardenafil were interchanged with minimal disruption to those being treated for erectile dysfunction.
Conclusions
Overall, the national formulary change from sildenafil to vardenafil was well tolerated by the vast majority of patients at this local VA hospital. The majority of non-formulary requests for sildenafil were made for patients who complained of therapeutic failure of vardenafil and had previously been satisfied with sildenafil. Biases in the study included the lack of knowledge of the ability to switch back to sildenafil, sildenafil-naive patients versus those who were previously treated with sildenafil, and lack of efficacy or intolerance to sildenafil. Prospective randomized studies are needed to truly compare the various PDE5 inhibitors and evaluate their interchangeability in the clinical setting. Source of funding: none Disclosures for M Singh: none. Disclosures for A Seftel: Pfizer, consultant.
